PMID- 29207634
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 53
DP  - 2017 Oct 31
TI  - Treatment plan comparison between Tri-Co-60 magnetic-resonance image-guided 
      radiation therapy and volumetric modulated arc therapy for prostate cancer.
PG  - 91174-91184
LID - 10.18632/oncotarget.20039 [doi]
AB  - To investigate the plan quality of tri-Co-60 intensity-modulated radiation 
      therapy (IMRT) with magnetic-resonance image-guided radiation therapy compared 
      with volumetric-modulated arc therapy (VMAT) for prostate cancer. Twenty patients 
      with intermediate-risk prostate cancer, who received radical VMAT were selected. 
      Additional tri-Co-60 IMRT plans were generated for each patient. Both primary and 
      boost plans were generated with tri-Co-60 IMRT and VMAT techniques. The 
      prescription doses of the primary and boost plans were 50.4 Gy and 30.6 Gy, 
      respectively. The primary and boost planning target volumes (PTVs) of the 
      tri-Co-60 IMRT were generated with 3 mm margins from the primary clinical target 
      volume (CTV, prostate + seminal vesicle) and a boost CTV (prostate), 
      respectively. VMAT had a primary planning target volume (primary CTV + 1 cm or 2 
      cm margins) and a boost PTV (boost CTV + 0.7 cm margins), respectively. For both 
      tri-Co-60 IMRT and VMAT, all the primary and boost plans were generated that 95% 
      of the target volumes would be covered by the 100% of the prescription doses. Sum 
      plans were generated by summation of primary and boost plans. In sum plans, the 
      average values of V70 Gy of the bladder of tri-Co-60 IMRT vs. VMAT were 4.0% +/- 
      3.1% vs. 10.9% +/- 6.7%, (p < 0.001). Average values of V70 Gy of the rectum of 
      tri-Co-60 IMRT vs. VMAT were 5.2% +/- 1.8% vs. 19.1% +/- 4.0% (p < 0.001). The doses 
      of tri-Co-60 IMRT delivered to the bladder and rectum were smaller than those of 
      VMAT while maintaining identical target coverage in both plans.
FAU - Park, Jong Min
AU  - Park JM
AD  - Department of Radiation Oncology, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Institute of Radiation Medicine, Seoul National University Medical Research 
      Center, Seoul, Republic of Korea.
AD  - Biomedical Research Institute, Seoul National University College of Medicine, 
      Seoul, Republic of Korea.
AD  - Robotics Research Laboratory for Extreme Environments, Advanced Institutes of 
      Convergence Technology, Suwon, Republic of Korea.
FAU - Park, So-Yeon
AU  - Park SY
AD  - Department of Radiation Oncology, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Institute of Radiation Medicine, Seoul National University Medical Research 
      Center, Seoul, Republic of Korea.
AD  - Biomedical Research Institute, Seoul National University College of Medicine, 
      Seoul, Republic of Korea.
FAU - Choi, Chang Heon
AU  - Choi CH
AD  - Department of Radiation Oncology, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Institute of Radiation Medicine, Seoul National University Medical Research 
      Center, Seoul, Republic of Korea.
AD  - Biomedical Research Institute, Seoul National University College of Medicine, 
      Seoul, Republic of Korea.
FAU - Chun, Minsoo
AU  - Chun M
AD  - Department of Radiation Oncology, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Institute of Radiation Medicine, Seoul National University Medical Research 
      Center, Seoul, Republic of Korea.
AD  - Biomedical Research Institute, Seoul National University College of Medicine, 
      Seoul, Republic of Korea.
FAU - Kim, Jin Ho
AU  - Kim JH
AD  - Department of Radiation Oncology, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Institute of Radiation Medicine, Seoul National University Medical Research 
      Center, Seoul, Republic of Korea.
AD  - Biomedical Research Institute, Seoul National University College of Medicine, 
      Seoul, Republic of Korea.
FAU - Kim, Jung-In
AU  - Kim JI
AD  - Department of Radiation Oncology, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Institute of Radiation Medicine, Seoul National University Medical Research 
      Center, Seoul, Republic of Korea.
AD  - Biomedical Research Institute, Seoul National University College of Medicine, 
      Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20170808
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5710914
OTO - NOTNLM
OT  - magnetic-resonance image-guided radiation therapy
OT  - prostate cancer
OT  - volumetric modulated arc therapy
COIS- CONFLICTS OF INTEREST The authors indicated no conflicts of interest.
EDAT- 2017/12/07 06:00
MHDA- 2017/12/07 06:01
PMCR- 2017/10/31
CRDT- 2017/12/07 06:00
PHST- 2017/06/13 00:00 [received]
PHST- 2017/07/25 00:00 [accepted]
PHST- 2017/12/07 06:00 [entrez]
PHST- 2017/12/07 06:00 [pubmed]
PHST- 2017/12/07 06:01 [medline]
PHST- 2017/10/31 00:00 [pmc-release]
AID - 20039 [pii]
AID - 10.18632/oncotarget.20039 [doi]
PST - epublish
SO  - Oncotarget. 2017 Aug 8;8(53):91174-91184. doi: 10.18632/oncotarget.20039. 
      eCollection 2017 Oct 31.